OpenAI's GPT-Rosalind agents surface cholesterol transport lead for neurodegenerative disease in 32 minutes
OpenAI · x · 2026-10-21
OpenAI says its GPT-Rosalind system surfaced a testable drug-discovery lead: DCTN1, a gene linked to Perry syndrome, appears to disrupt cholesterol-related gene expression in mouse-brain data, suggesting neurons may be starved of cholesterol transport — a possible route to new neurodegenerative treatments.
Working with Perturb.ai and Scripps Research, thousands of GPT-Rosalind agents ran in parallel, connecting gene-expression results from millions of mouse brain cells with scientific literature in just 32 minutes. The collaboration is now expanding to identify new drug targets; the same dataset also yielded a clue on why TSC2 mutations cause more severe tuberous sclerosis than TSC1.
Related event: OpenAI's GPT-Rosalind Mines Mouse Brain Data for Drug Discovery Clues(2 posts)→
More from AGI Musings
- Recursive generalization makes neurons 'clean' — agent swarms could crash alignment costs to 7 figures — daniel_mac8 · 2026-10-21
- Cloudflare: Bots Hit 57.5% of Web Traffic, Agent Traffic to 1000x Human in 5 Years — shashib · 2026-10-21
- Over Half of Managers Say AI Made Evaluating Employees' Work Harder — TechCrunch AI · 2026-10-21
- David Patterson: The ChatGPT Moment for Robots Will Come From ChatGPT Itself — davidpattersonx · 2026-10-21
- slopcore is mostly derivative garbage — even with AI, content still requires taste — rickasaurus · 2026-10-21
- AI confusion problem: fear-spreading voices drown out real value and real risks — DavidLinthicum · 2026-10-21